CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 706 enrolled
Drug / intervention
pembrolizumab + epacadostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02752074
NCT02752074Phase 3Completed
CompareCT.gov

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Incyte Corporation·interventional·Posted Apr 26, 2016·Updated Aug 24, 2025

In Brief

A Phase 3 clinical trial evaluating pembrolizumab + epacadostat and pembrolizumab + placebo for Melanoma. Completed, enrolled 706 participants across 129 sites in 23 countries.

Detailed Summary

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesAustralia, Belgium, Canada, Chile, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 26, 2016
Enrollment StartJun 21, 2016
Primary CompletionJan 8, 2018
Study CompletionAug 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.2 years ago

Interventions

pembrolizumab + epacadostatdrug

* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Epacadostat will be administered orally daily starting at Day 1 (Week 1)

pembrolizumab + placebodrug

* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Placebo will be administered orally daily starting at Day 1 (Week 1)